Stockscreener 앱 받기
172.38
1.53%
-2.68
시장 영업 전:
172.38
전일 마감가:
$175.06
열려 있는:
$174.16
하루 거래량:
1.52M
Relative Volume:
0.75
시가총액:
$28.77B
수익:
$16.63B
순이익/손실:
$1.39B
주가수익비율:
21.37
EPS:
8.0674
순현금흐름:
$2.12B
1주 성능:
-2.32%
1개월 성능:
+0.23%
6개월 성능:
-22.89%
1년 성능:
+14.40%
1일 변동 폭
$168.07
$176.26
1주일 범위
$168.07
$182.62
52주 변동 폭
$134.65
$247.04
아이큐비아 홀딩스 Stock (IQV) Company Profile
명칭
Iqvia Holdings Inc
전화
919-998-2000
주소
2400 ELLIS ROAD, DURHAM, NC
Compare IQV vs TMO, DHR, IDXX, WAT, A
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IQV
Iqvia Holdings Inc
|
172.38 | 29.22B | 16.63B | 1.39B | 2.12B | 8.0674 |
TMO
Thermo Fisher Scientific Inc
|
446.03 | 170.69B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
165.99 | 117.67B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
528.68 | 42.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
334.93 | 34.57B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
112.74 | 31.91B | 7.07B | 1.29B | 993.00M | 4.5355 |
아이큐비아 홀딩스 Stock (IQV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-09 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-03-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2026-03-03 | 개시 | RBC Capital Mkts | Outperform |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-11-13 | 개시 | BMO Capital Markets | Outperform |
| 2025-11-03 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-10-29 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-09 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-04-25 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-04-10 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-02-03 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-20 | 개시 | Stephens | Overweight |
| 2024-10-14 | 개시 | Redburn Atlantic | Buy |
| 2024-09-04 | 개시 | RBC Capital Mkts | Outperform |
| 2024-07-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-02-13 | 개시 | BTIG Research | Buy |
| 2023-11-02 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-03-17 | 개시 | Truist | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-11-17 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-15 | 개시 | SVB Leerink | Outperform |
| 2022-05-24 | 개시 | Guggenheim | Buy |
| 2022-04-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-16 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-03-08 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2020-07-07 | 개시 | Stephens | Equal-Weight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | CFRA | Sell → Hold |
| 2019-11-14 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2019-06-21 | 업그레이드 | Mizuho | Neutral → Buy |
| 2019-05-28 | 개시 | SVB Leerink | Outperform |
| 2019-01-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-10-02 | 재확인 | Robert W. Baird | Outperform |
| 2018-07-25 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2018-07-25 | 재확인 | Stifel | Buy |
| 2018-07-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-04-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-03-07 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-01-19 | 개시 | Evercore ISI | Outperform |
모두보기
아이큐비아 홀딩스 주식(IQV)의 최신 뉴스
Why (IQV) Price Action Is Critical for Tactical Trading - Stock Traders Daily
IQVIA expands collaboration with Kexing Biopharm on biosimilars - Investing.com
IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IQVIA expands collaboration with Kexing Biopharm on biosimilars By Investing.com - Investing.com Canada
AI-powered trials to speed global biosimilar drugs in IQVIA-Kexing pact - Stock Titan
IQVIA Holdings stock (US46266C1053): Global leader in healthcare data analytics - AD HOC NEWS
IQVIA Q1 2026 slides: earnings beat drives guidance raise By Investing.com - Investing.com Canada
IQVIA Q1 2026 slides: earnings beat drives guidance raise - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges - Investing.com
Earnings call transcript: IQVIA surpasses Q1 2026 forecasts, stock surges By Investing.com - Investing.com Australia
IQVIA’s Q1 Earnings Call: Our Top 5 Analyst Questions - Barchart.com
IQVIA Holdings Inc. stock outperforms competitors on strong trading day - MSN
IQVIA (NYSE: IQV) director granted 171 deferred shares at $178.64 - Stock Titan
IQVIA (NYSE: IQV) director Colleen Goggins receives 214 Deferred Shares grant - Stock Titan
IQVIA (NYSE: IQV) director Jim Fasano receives 228 deferred share award - Stock Titan
IQVIA (NYSE: IQV) director awarded 185 deferred shares with 1:1 common conversion - Stock Titan
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why is Larry Robbins Bullish on IQVIA Holdings (IQV) Amid Market Volatility - Kavout
IQVIA Holdings Inc. (IQV): Larry Robbins Is Bullish on This Stock - Insider Monkey
Why IQVIA Holdings (IQV) Is Up 12.8% After Q1 Beat and Bigger Buyback Plan – And What's Next - Sahm
Dark Horse Consulting Group and KunTuo Announce Memorandum of Understanding Providing Cell and Gene Therapy Developers with an Accelerated Path to Clinical Development in China - GlobeNewswire Inc.
IQVIA Holdings, Inc. (IQV) Stock Analysis: Robust Growth Potential With A 27.92% Upside - DirectorsTalk Interviews
IQVIA Holdings earnings preview: What to expect - MSN
IQVIA Q1 Earnings Call Highlights - sharewise.com
Here's why you should retain IQV stock in your portfolio now - MSN
IQVIA Holdings stock (US46266C1053): Data?driven healthcare analytics in focus for US investors - AD HOC NEWS
IQVIA board authorizes additional $2B in share repurchases - MSN
IQVIA Expands Share Repurchase Authorization by $2 Billion - The Globe and Mail
BMO Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210 - Moomoo
IQVIA Holdings Inc. (NYSE:IQV) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st
IQVIA Holdings | 8-K: Current report - Moomoo
Earnings Update: IQVIA Holdings Inc. (NYSE:IQV) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - Yahoo Finance
IQVIA Increases Share Repurchase Authorization by $2 Billion, Bringing Total to $3.2 Billion 1 - Minichart
Artificial Intelligence in Epidemiology Market Is Going - openPR.com
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization - The National Law Review
IQVIA Board Approves $2B Increase to Share Repurchase Authorization, $3.2B Remaining - TradingView
IQVIA board authorizes additional $2 billion stock buyback - Investing.com
IQVIA board authorizes additional $2 billion stock buyback By Investing.com - Investing.com Australia
IQVIA (NYSE: IQV) boosts buyback plan, $3.2B now authorized - Stock Titan
IQVIA Holdings (IQV) Q1 earnings and revenues beat estimates - MSN
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Contineum Therapeutics, Inc. Class A (CTNM) and Exelixis (EXEL) - The Globe and Mail
Barclays Sticks to Their Buy Rating for IQVIA Holdings (IQV) - The Globe and Mail
IQVIA Holdings (IQV) Earnings Growth And 8.3% Margin Keep Backlog Narrative In Question - Sahm
IQVIA CFO to Speak at Bank of America Health Care Conference 2026 - BioSpace
IQVIA Holdings Hits Day High with 9.62% Surge in Stock Price - Markets Mojo
Citigroup Maintains IQVIA Holdings (IQV) Neutral Recommendation - MSN
IQVIA Holdings | 8-K: IQVIA Reports First-Quarter 2026 Results - Moomoo
IQVIA Holdings Inc. announces an Increase in Equity Buyback. - marketscreener.com
아이큐비아 홀딩스 (IQV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.35%
0.35%
자본화:
|
볼륨(24시간):